BiotechTube

Sitafloxacin + Moxifloxacin Hydrochloride

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

COPD Exacerbation Acute

Conditions

COPD Exacerbation Acute

Trial Timeline

Aug 10, 2022 โ†’ Sep 25, 2024

NCT ID
NCT05400369

About Sitafloxacin + Moxifloxacin Hydrochloride

Sitafloxacin + Moxifloxacin Hydrochloride is a approved stage product being developed by Daiichi Sankyo for COPD Exacerbation Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT05400369. Target conditions include COPD Exacerbation Acute.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT05400369ApprovedCompleted

Competing Products

20 competing products in COPD Exacerbation Acute

See all competitors
ProductCompanyStageHype Score
Reldesemtiv + PlaceboAstellas PharmaPhase 2
52
Lysozyme hydrochloride + PlaceboEisaiApproved
85
Arformoterol (Brovana) + PlaceboSumitomo PharmaApproved
85
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Salmeterol MDI + PlaceboSumitomo PharmaPhase 3
77
Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Placebo + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + Arformoterol tartrate inhalation solution + PlaceboSumitomo PharmaPhase 2
52
Arformoterol tartrate inhalation solution + TiotropiumSumitomo PharmaApproved
85
Racemic formoterol + Arformoterol tartrate inhalation solution + Racemic formoterolSumitomo PharmaPhase 2
52
Levalbuterol HCl + Levalbuterol HCl + Albuterol Sulfate + PlaceboSumitomo PharmaPhase 3
77
Formoterol Turbuhaler + Budesonide/Formoterol Turbuhaler + Formoterol TurbuhalerAstraZenecaPhase 1
33
AZD2115 + Placebo + Indacaterol + Indacaterol + TiotropiumAstraZenecaPhase 2
52
RoflumilastAstraZenecaPhase 2/3
65
Aclidinium bromide + PlaceboAstraZenecaPhase 3
77
RoflumilastAstraZenecaPre-clinical
23
Symbicort (budesonide/formoterol turbuhaler 320/9ug) + Spiriva (tiotropium bromide 18ug)AstraZenecaApproved
85
AZD7624 + Placebo to matchAstraZenecaPhase 1
33
Roflumilast + PlaceboAstraZenecaPhase 3
77
Aclidinium bromide 100 ฮผg bid + Aclidinium bromide 200 ฮผg bid + Aclidininum bromide 400 ฮผg bid + Placebo + Formoterol 12 ฮผg bidAstraZenecaPhase 2
52
ACL/FOR + PlaceboAstraZenecaApproved
85
TozorakimabAstraZenecaPhase 2
52
AZD1981 + PlaceboAstraZenecaPhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85